10-Q quarterly report · filed Nov 10, 2026

Sionna Therapeutics, Inc. (SION) Q3 2026 10-Q Quarterly Report

Short answer

Sionna Therapeutics, Inc. (SION) filed its Q3 2026 10-Q quarterly report on Nov 10, 2026 for the quarter ended Sep 30, 2026.

Q3 2026 key financials · XBRL

Net income
−$32M
−59.9% YoY · −8.5% QoQ
EPS (diluted)
−$0.73
−100.1% YoY · −12.3% QoQ

Source: XBRL data from the Sionna Therapeutics, Inc. (SION) Q3 2026 10-Q on SEC EDGAR. USD.

Sionna Therapeutics, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, no product sales
  • Net loss $32.4M vs $20.3M YoY, operating margin not applicable
  • NBD1 and combination R&D $10.5M vs $8.6M, strongest program spending
  • Cash, equivalents and marketable securities $249.8M, runway into second half of 2029
  • Operating cash use $62.8M vs $49.7M; workforce reduction approximately 46%, SION-451 plus SION-2222 Phase 2 expected Q1 2027

Risk Factors

  • Newly triggered supply-chain risk: BIOSECURE Act exposure after a Chinese manufacturer joined the Section 1260H list on June 8, 2026
  • Most updated clinical risk: SION-719 discontinuation after PreciSION CF missed its sweat-chloride endpoint, concentrating prospects on SION-451 + SION-2222
  • Regulatory risk: FDA scrutiny of foreign clinical data could require additional trials for U.S. approval
  • Near-term operational risk: AscenSION CF requires patients to switch from Trikafta, increasing enrollment and retention challenges
  • Financial risk: $249.8 million cash, cash equivalents and marketable securities expected to fund operations into the second half of 2029

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Sionna Therapeutics, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.